Trial Profile

Phase II, Single-arm Clinical Trial Evaluating Efficacy and Safety of Pembrolizumab in Combination With a Soluble LAG-3 Protein, Eftilagimod Alpha, and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcomas (EFTISARC-NEO)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eftilagimod alpha (Primary) ; Pembrolizumab (Primary)
Indications Haemangiosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Sarcoma; Soft tissue sarcoma
Focus Therapeutic Use
Acronyms EFTISARC-NEO
Sponsors Immutep Limited

13 Nov 2025 According to an Immutep media release, data from this trial was presented at the National Research Institute of Oncology, Warsaw, Poland, at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting held in Boca Raton, Florida.
13 Nov 2025 Results presented in the Immutep media release.
20 Oct 2025 Results presented in the Immutep media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com